menu search

Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting

– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class ...

November 3, 2023, 8:05 pm

Kineta reports third quarter 2023 financial results and provides corporate update

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in comb...

November 3, 2023, 8:01 pm

Galectin therapeutics to share five scientific presentations at the liver meeting™ 2023, hosted by the aasld

pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of bela...

November 3, 2023, 12:00 pm

Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...

October 25, 2023, 9:05 am

Eagle pharmaceuticals awarded first prize for poster to be presented at the international society for anaesthetic pharmacology 32nd annual meeting

— Study reports on an interim analysis of the pharmacokinetics and pharmacodynamics of remimazolam an...

October 4, 2023, 10:50 am

Sensei biotherapeutics to present new preclinical data supporting mechanism of action, pharmacokinetic profile and safety characteristics for sns-101, a conditionally active vista-blocking antibody, a

BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the disco...

September 13, 2023, 11:30 am

Apogee therapeutics: potential to target autoimmune disorders with less frequent dosing

Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healt...

August 22, 2023, 8:14 am

Acasti to present gtx-104 pharmacokinetic comparison data at neurocritical care annual meeting

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company adva...

August 9, 2023, 4:05 pm

Apogee announces first participants dosed ahead of schedule in phase 1 trial of apg777, its novel half-life extended anti-il-13 antibody for the treatment of atopic dermatitis and other inflammatory d

Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every two-...

August 7, 2023, 11:30 am

Ambrx to present preliminary arx517 first-in-human safety, efficacy, and pharmacokinetics data at esmo 2023

Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting Presentations represent the first time cl...

July 28, 2023, 8:30 am

Oxford cannabinoid technologies takes pain drug into phase i; appoints leading pain expert

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) said it has commenced its phase I clinical trial for the lead drug candidate, OC...

July 27, 2023, 2:49 am

Aquestive therapeutics: developing a better solution to a $1 billion/year anaphylaxis problem

Anaphylm, epinephrine sublingual film is a better solution to existing and in-development epinephrine formulations to treat anaphylaxis, a $1 billion/...

July 25, 2023, 8:37 pm

Urica therapeutics announces topline data from the phase 1 clinical trial evaluating dotinurad in healthy volunteers in the united states

Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic...

June 29, 2023, 12:00 pm

Biora therapeutics presents data on the biojet™ systemic oral delivery platform at the american diabetes association 83rd scientific sessions

An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) — Biora Therapeutic...

June 26, 2023, 10:00 am

Chinook therapeutics presents data from chk-336 phase 1 trial in healthy volunteers and new insights into the role of failed repair in chronic kidney disease at the 60th european renal association (er

CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days ...

June 17, 2023, 11:15 am

Chinook therapeutics presents data from chk-336 phase 1 trial in healthy volunteers and new insights into the role of failed repair in chronic kidney disease at the 60th european renal association (er

CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days ...

June 17, 2023, 11:15 am

Chinook therapeutics presents data from chk-336 phase 1 trial in healthy volunteers and new insights into the role of failed repair in chronic kidney disease at the 60th european renal association (er

CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days ...

June 17, 2023, 11:15 am

Chinook therapeutics presents data from chk-336 phase 1 trial in healthy volunteers and new insights into the role of failed repair in chronic kidney disease at the 60th european renal association (er

CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days ...

June 17, 2023, 11:15 am


Search within

Pages Search Results: